COVID-19 booster vaccination/booster vaccination
In the practice of DR. FRÜHWEIN & PARTNER in Munich
COVID-19 vaccines provide effective and sustained protection against severe illness and death from SARS-COV-2, although they cannot be used to safely rule out infection. Nevertheless, the risk of infection with COVID-19 is reduced and thus the risk of transmission to contact persons is also minimized. Unvaccinated persons are thus particularly at risk.
As with most vaccinations, vaccine protection wears off over time, especially in terms of preventing infections without symptoms or with mild courses of disease. Vaccinations are less effective in older or immunocompromised patients due to the limited immune response, which is why vaccination breakthroughs can lead to more severe courses of the disease.
Which vaccine composition?
The WHO regularly updates its recommendations on the composition of COVID-19 vaccines. As the virus is constantly changing and new variants are constantly circulating, adjustments are necessary to ensure adequate protection.
For the 2025/2026 season, vaccines against the LP 8.1 variant are recommended. Against variant LP 8.1. The two mRNA vaccines Spikevax (Moderna) and Comirnaty (Biontech) are currently available against the LP 8.1 variant. The protein-based vaccine Nuvaxovid (Novavax) contains the JN.1 variant.
Available booster vaccines against COVID-19
The following vaccines are available in Germany this season:
<h2>Comirnaty</h2>
<h3>Biontech / Pfizer</h3>
Touch with the mouse pointer for more information.
<h2>Comirnaty</h2>
<h3>Biontech / Pfizer</h3>
Trade name:
Comirnaty
Manufacturer:
Biontech/Pfizer
Vaccine type:
mRNA
Approved since:
21.12.2020
<h2>Spikevax</h2>
<h3>Moderna Biotech</h3>
Touch with the mouse pointer for more information.
<h2>Spikevax</h2>
<h3>Moderna Biotech</h3>
Trade name:
Spikevax (COVID-19 Vaccine Moderna)
Manufacturer:
Moderna Biotech
Vaccine type:
mRNA
Approved since:
06.01.2021
<h2>Nuvaxovid</h2>
<h3>Novavax</h3>
Touch with the mouse pointer for more information.
<h2>Nuvaxovid (NVX-CoV2373)</h2>
<h3>Novavax</h3>
Trade name:
Nuvaxovid JN.1
Manufacturer:
Novavax
Vaccine type:
Protein
Approved since:
20.12.2021